Citation

de Haro L, Glaizal M, Tichadou L, Blanc-Brisset I, Hayek-Lanthois M. Toxins (Basel) 2009; 1(2): 100-112.

Affiliation

Centre Antipoison, hôpital Salvator, 249 boulevard Sainte Marguerite, 13009 Marseille, France; Email: mathieu.glaizal@ap-hm.fr (M.G.); lucia.tichadou@ap-hm.fr (L.T.); ingrid.blanc@ap-hm.fr (I.B.-B.); maryvonne.hayek@ap-hm.fr (M.H.-L.).

Copyright

(Copyright © 2009, MDPI: Multidisciplinary Digital Publishing Institute)

DOI

10.3390/toxins1020100

PMID

22069534

PMCID

PMC3202779

Abstract

A retrospective case review study of viper envenomations collected by the Marseille's Poison Centre between 1996 and 2008 was performed. RESULTS: 174 cases were studied (52 grade 1 = G1, 90 G2 and 32 G3). G1 patients received symptomatic treatments (average hospital stay 0.96 day). One hundred and six (106) of the G2/G3 patients were treated with the antivenom Viperfav* (2.1+/-0.9 days in hospital), while 15 of them received symptomatic treatments only (plus one immediate death) (8.1+/-4 days in hospital, 2 of them died). The hospital stay was significantly reduced in the antivenom treated group (p < 0.001), and none of the 106 antivenom treated patients had immediate (anaphylaxis) or delayed (serum sickness) allergic reactions. CONCLUSION: Viperfav* antivenom was safe and effective for treating asp viper venom-induced toxicity.

Language: en